News | April 28, 2022
Sanofi continues to deliver strong business
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The first use of Philips' breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter
The data driven fertility company helps increase the success rate of fertility treatments
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
The initial courses of Lap. Hernia Masterclass will encompass commonly performed hernia procedures
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Subscribe To Our Newsletter & Stay Updated
